Detection of Disease-Related Changes in Pre-Symptomatic Alzheimer's Disease

We will take pictures of subjects' brains using PET imaging, in healthy older adults (ages
55 to 80 years) who have both a family history of AD, and who have concerns about changes in
their memory (but no clinical symptoms of AD), to see how much of a protein - that is
related to AD -is in their brains. When all subjects come to the hospital for PET imaging,
we will review the entire study plan with them, the risks and benefits of participation, and
we will obtain written informed consent at that time. Our goal is to compare performance on
our new stress test to these PET imaging results. Once the PET imaging is done, we will have
each subject come to our clinical research unit for a day-long baseline visit. In the
morning we will give the tests of memory and thinking, and then we will administer the
injection of scopolamine at a very low dose. We will then continue to examine the subjects,
and to give the memory and thinking tests at 1, 3, 5, 7, and 8 hours post-dosing. Once they
have fully-recovered from all effects of the medication, they will be allowed to go home
that day. We will then see all subjects again, for much shorter visits to complete the
cognitive tests, at both 9 and 18 months after their initial study visit. We will follow all
subjects for 18 months to see which of them show very mild but measurable changes on the
memory and thinking tests, as we predict that these will be the same persons who also had
stronger results on our stress test at the first study visit.

At all three study visits to our clinical research unit, we will obtain measurements using
an imaging device that uses infrared and blue light to take picture of the eye and retina.
Our secondary goal in this study to search for evidence of the same protein, in the retina,
that builds up and is seen with PET imaging of the brain in persons who are at high risk for
AD. Finally, we are also collecting a small sample of saliva, at the first visit to our
unit, in order to see which subjects have a genetic risk for the disease, as this genetic
risk may affect how we interpret the results of our new "cognitive stress test".

In this study, a small dose of an already approved medication (used to treat seasickness)
will be used to temporarily, and safely, mimic signs of very early disease during just the
first day of testing. This is a methodological study to determine if tests that measure how
you think can predict the risk of dementia as we age.

Inclusion Criteria:

- Individuals between the ages of 55 and 80 years old (inclusive).

- MMSE total score > 27

- Two risk factors for AD:

- Subjective memory complaints.

- A positive (suspected) first-degree family history for the disease.

- Permitted medications stable for at least 1 month prior to screening.

- Subjects may take stable doses of antidepressants lacking significant anticholinergic
side effects (do not have a history of major depression within the past year).

- Estrogen replacement therapy.

- Adequate visual and auditory acuity to allow neuropsychological testing.

- Good general health or without any clinically significant abnormalities .

- Vitamin supplements (including Vitamin E) will be acceptable.

- Subjects must be willing and able to provide written informed consent.

Exclusion Criteria:

- History of major traumatic brain injury, other known neurologic disease or insult

- Mini Mental State Examination (MMSE)total score < 27

- Regular (daily) use of narcotics or antipsychotic medications

- Poorly-controlled major depression or another Axis I psychiatric disorder as
described in DSM-IV within the past year.

- Psychotic features, agitation or behavioral problems, within the last 3 months.

- History of alcohol or substance abuse or dependence within the past 2 years (DSM IV
criteria).

- History of schizophrenia (DSM IV criteria).

- Any significant systemic illness or unstable medical condition which could lead to
difficulty complying with the protocol including:

- History of systemic cancer within the past 5 years (non-metastatic skin cancers are
acceptable).

- History of myocardial infarction in the past year or unstable or severe
cardiovascular disease including angina or Congestive Heart Failure (CHF) with
symptoms at rest.

- Clinically significant obstructive pulmonary disease or asthma.

- Clinically significant and unstable gastrointestinal disorder within two years.

- Insulin-requiring diabetes or uncontrolled diabetes mellitus.

- Uncontrolled hypertension (systolic BP > 170 or diastolic BP > 100).

- History of clinically significant liver disease, coagulopathy, or vitamin K
deficiency within the past 2 years.

- History of symptoms of narrow-angle glaucoma.

- Clinically significant obstructive uropathy

- Use of centrally active beta-blockers, narcotics, methyldopa and clonidine within 4
weeks prior to screening.

- Use of anti-Parkinsonian medications (e.g., Sinemet, amantadine, bromocriptine,
pergolide and selegiline) within 2 months prior to screening.

- Use of neuroleptics or narcotic analgesics within 4 weeks prior to screening.

- Use of long-acting benzodiazepines or barbiturates within 4 weeks prior to screen.

- Use of short-acting anxiolytics or sedative-hypnotics more frequently than 2 times
per week within 4 weeks prior to screening (note: sedative agents should not be used
within 72 hours of the baseline and follow-up visits.

- Initiation or change in dose of an antidepressant lacking significant cholinergic
side effects within the 4 weeks prior to screening (use of stable doses of
antidepressants for at least 4 weeks prior to screening is acceptable)

- Use of systemic corticosteroids within 3 months prior to screening.

- Medications with significant cholinergic or anticholinergic side effects within 4
weeks prior to screening.

- Use of anti-convulsants within 2 months prior to screening.

- Use of warfarin (Coumadin) within 4 weeks prior to screening.

- Any prior use of any FDA approved medications for the treatment of Alzheimer's
disease (e.g., tacrine, donepezil, or other newly approved medications).

- Use of any investigational drugs within 30 days or 5 half-lives, whichever is longer,
prior to screening.

- Subjects who, in the investigator's opinion, will not comply with study procedures.

- Known hypersensitivity to F-18, tropicamide, and/or scopolamine or agents of this
class of drugs.